Epistaxis and perforation of hollow organs of abdomen caused by lenvatinib
10.3760/cma.j.cn114015-20200203-00082
- VernacularTitle:仑伐替尼致鼻出血和腹部空腔脏器穿孔
- Author:
Huabo WEI
1
;
Bo LI
;
Xia LI
;
Yang DONG
Author Information
1. 重庆市丰都县人民医院药剂科，重庆 408200
- Publication Type:Journal Article
- Keywords:
Antineoplastic;
Cancer;
Hepatocellular carcinoma;
Epistaxis;
Enterobrosis;
Receptor protein-tyrosine kinases;
Lenvatinib
- From:
Adverse Drug Reactions Journal
2020;22(12):709-710
- CountryChina
- Language:Chinese
-
Abstract:
A 56-year-old male patient with advanced hepatocellular carcinoma received targeted therapy with lenvatinib 12 mg once daily. After 30 days of medication, the patient developed epistaxis without predisposing factors in the morning, which occurred once every half a month and could be stopped after compression. The drug was not stopped. After 97 days of medication, the patient developed abdominal pain. Physical examination showed abdominal tenderness, especially in the upper and middle abdomen, rebound pain, and muscle tension. Abdominal CT examination showed pneumoperitoneum, hydrops, and perforation of hollow organs of abdomen. Lenvatinib was withdrawn and the conservative treatments with fasting, gastrointestinal decompression, anti-infection, acid suppression, and rehydration were given. After 22 days of treatments, his abdominal pain was relieved and the fluid diet was restored. After 26 days of treatments, the patient had exhaust and defecation. After that, the patient took lenvatinib with the same dose as before by himself again for one week, and epistaxis recurred. There was no epistaxis after discontinuation of lenvatinib again. It was considered that epistaxis and perforation of hollow organs might be related to lenvatinib.
